InnoCare Pharma Limited
INCPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,009 | $739 | $625 | $1,043 |
| % Growth | 36.7% | 18.1% | -40% | – |
| Cost of Goods Sold | $138 | $128 | $143 | $66 |
| Gross Profit | $871 | $610 | $482 | $977 |
| % Margin | 86.3% | 82.6% | 77.1% | 93.7% |
| R&D Expenses | $814 | $751 | $639 | $722 |
| G&A Expenses | $48 | $49 | $51 | $46 |
| SG&A Expenses | $311 | $252 | $613 | $345 |
| Sales & Mktg Exp. | $263 | $204 | $259 | $298 |
| Other Operating Expenses | $272 | $258 | $0 | $75 |
| Operating Expenses | $1,397 | $1,261 | $1,252 | $1,141 |
| Operating Income | -$526 | -$651 | -$770 | -$181 |
| % Margin | -52.1% | -88.2% | -123.2% | -17.4% |
| Other Income/Exp. Net | $73 | $7 | -$123 | $161 |
| Pre-Tax Income | -$453 | -$644 | -$894 | -$20 |
| Tax Expense | $0 | $1 | $0 | $47 |
| Net Income | -$441 | -$631 | -$887 | -$65 |
| % Margin | -43.7% | -85.5% | -141.8% | -6.2% |
| EPS | -0.26 | -0.37 | -0.6 | -0.037 |
| % Growth | 29.7% | 38.3% | -1,539.3% | – |
| EPS Diluted | -0.26 | -0.37 | -0.6 | -0.037 |
| Weighted Avg Shares Out | 1,691 | 1,706 | 1,480 | 1,764 |
| Weighted Avg Shares Out Dil | 1,691 | 1,706 | 1,480 | 1,764 |
| Supplemental Information | – | – | – | – |
| Interest Income | $172 | $192 | $137 | $135 |
| Interest Expense | $34 | $35 | $17 | $3 |
| Depreciation & Amortization | $106 | $93 | $68 | $15 |
| EBITDA | -$313 | -$517 | -$808 | -$167 |
| % Margin | -31% | -69.9% | -129.2% | -16% |